We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Complete Genomics Partners with Inova Health System to Sequence the Genomes of 500 Infants and Their Parents

By LabMedica International staff writers
Posted on 22 Sep 2011
Print article
Complete Genomics, Inc. (Mountain View, CA, USA), a human genome sequencing company, and Inova Health System (Falls Church, VA, USA), a not-for-profit healthcare system, announced additional details about their partnership to sequence 1,500 genomes from 500 infants and their parents. The goal of this project is to identify prognostic, diagnostic, and therapeutic targets for pre-term delivery and potentially other obstetrics-associated abnormalities.

This project was first announced during Complete Genomics’ Q2 earnings call on August 4, 2011. This partnership is part of a pilot program with the Inova Translational Medicine Institute (ITMI), a not-for-profit research institute within the Inova Health System geared at translating clinical research into actual care programs using genomically driven patient care, frequently referred to as personalized medicine.

“Complete Genomics is a natural choice as our sequencing partner for this new program,” said John Niederhuber, CEO, Inova Translational Medicine Institute. “We are confident that Complete Genomics can manage a large project of this type efficiently and produce the consistent, high-quality sequencing data that we need to be able to understand the subtle genetic changes that contribute to pre-term delivery.”

“The Inova Translational Medicine Institute is truly an innovator in the delivery of patient care, striving to not only understand the genomic makeup of patients, but also to customize care to the individual to help prevent or manage their diseases,” said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. “We view this as an important opportunity for our sequencing service to potentially help create new treatment options for some of the smallest and sickest patients in the hospital.”

ITMI has already begun collecting DNA samples for Complete Genomics to begin sequencing in September. Complete Genomics will begin delivering variant reports to ITMI as early as Q4 and expects to complete most of the 1,500 genomes in the first quarter of 2012. These results will detail how the genomes of pre-term delivery babies from Inova Fairfax Hospital’s Joint Commission-certified neonatal intensive care unit (NICU) compare with reference genomes. They will include data about the single nucleotide polymorphisms (SNPs), insertions/deletions, copy number variations, and structural variations included in each DNA sample, together with the read alignments supporting those calls, coverage information and quality scores. In addition to sequence-based data, ITMI will also generate epigenomic, expression, and micro-RNA data on each sample. Data from Inova Health System's electronic medical record system will support ITMI’s outcomes-based research.

Complete Genomics is a human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA Platform) combines Complete Genomics’ proprietary human genome sequencing technology with advanced informatics and data management software. This solution is offered as an, outsourced service, CGA Service, and provides customers with data that is immediately ready to be used for genome-based research.

Related Links:
Complete Genomics
Inova Health System
Inova Translational Medicine Institute


New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Thyroid ELISA Kit
AESKULISA a-TPO
New
Sulfidoleukotrienes (sLT) Assay
CAST ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.